Forty‑six percent is not a rounding error; it is a reset of risk. A new study reports that men who received the human papillomavirus, or HPV, vaccine had a 46 percent reduction in HPV‑related cancers, including malignancies of the oropharynx, anus, and penis. Into a debate long framed around cervical cancer steps a stark reminder: HPV is an equal‑opportunity carcinogen.

The uncomfortable truth is that boys have been treated as bystanders in a virus they help transmit. HPV infects epithelial cells, drives persistent infection, and can trigger oncogenic changes in both sexes through mechanisms that include viral oncoproteins E6 and E7. The vaccine interrupts this process by inducing neutralizing antibodies before sexual exposure, a form of primary prevention that oncologists quietly wish existed for many other tumors.

Dr. Leana Wen argues that leaving boys and men unvaccinated squanders that advantage. She points to the rising burden of HPV‑driven head and neck cancers in men and the safety record of the recombinant virus‑like particle vaccines, which show robust immunogenicity and low rates of serious adverse events. Treating HPV vaccination as a girls‑only intervention is not just outdated; it is a missed chance to shrink the cancer burden for everyone.